RBC Capital Maintains Outperform on Knight Therapeutics, Raises Price Target to C$8

Benzinga · 5d ago
RBC Capital analyst Douglas Miehm maintains Knight Therapeutics (TSX:GUD) with a Outperform and raises the price target from C$7 to C$8.